Unforgivable Hypocrisy From FDAs Career CDER Leadership

The FDA leadership team’s hesitancy on Trump’s nCoV-2019 vaccines and hydroxychloroquine somehow didn’t apply to Biogen’s Aduhelm (aducanumab) review. The same career FDA bureaucrat who loudly crowed about “following the science” to discredit President Trump has approved a failed Alzheimer’s drug. Over the past couple weeks, Americans have heard a great deal about FDA’s recent approval of aducanumab (aka Aduhelm) as a treatment for Alzheimer’s Disease (AD).

Read the source article at forbes.com
2021-07-19 01:00:00